Anna Suk-Fong Lok, MD

Anna Suk-Fong Lok, MD, is the Alice Lohrman Andrews Research Professor of Hepatology in the Department of Internal Medicine, at Michigan Medicine in Ann Arbor, Michigan. Dr. Lok obtained her medical degree from the University of Hong Kong and her hepatology training under the late Dame Sheila Sherlock at the Royal Free Hospital in London, UK. She was on the faculty at the University of Hong Kong until she moved to the United States in 1992. Dr. Lok received one of the University of Michigan’s top honors in 2019 - Dame Sheila Sherlock Distinguished University Professor of Hepatology and Internal Medicine.

Dr. Lok's research focuses on the natural history and treatment of hepatitis B and C, and the prevention of liver cancer. She has published more than 600 papers on viral hepatitis and liver diseases and is the coauthor of 5 editions of the American Association for the Study of Liver Diseases Association Guidelines on Hepatitis B. She was one of the top 1% of most cited scientists in the world for the decade 2002-2012. Dr. Lok has trained more than 80 fellows and junior faculty from all over the world, some of whom have risen to the ranks of full professors and directors of liver programs in their home country. She received a Distinguished Mentor Award from the Michigan Institute of Clinical and Health Research in 2012, an Inspirational Physician Award from the American Medical Association in 2014, and a Distinguished Mentor Award from the American Gastroenterological Association in 2022. She was inducted into the Clinical Excellence Society in the Department of Internal Medicine in 2013.

Dr. Lok has received many awards throughout her career. She has been included in the list of Best Doctors and Who's Who for many years. She was inducted into the Association of American Physicians in 2012 and elected to the National Academy of Medicine in 2022.

She has received numerous awards from all over the world for her research in liver diseases and service to the hepatology community and to patients with liver diseases. These include the Distinguished Scientist Award from the Hepatitis B Foundation in 2008, the Distinguished Women Scientist Award from the American Gastroenterological Association in 2008, the Distinguished Service Award from the American Association for the Study of Liver Diseases in 2011, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2015, the William Beaumont Prize in Gastroenterology from the American Gastroenterological Association in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver, an Honorary Doctor of Science degree from the University of Hong Kong in 2017, and the International Recognition Award from the European Association for the Study of the Liver in 2018.

Dr. Lok served as an associate editor of Hepatology in 2001-2006, a co-editor of the Journal of Viral Hepatitis in 2007-2009, and a senior associate editor of Gastroenterology in 2011-2012. She is currently an Associate Editor for Hepatology Communications.

Dr. Lok was the President of the American Association for the Study of Liver Diseases in 2017.

Viral Hepatitis (B and C), liver disease, cirrhosis

University of Michigan Health participates with most health insurance plans.

Ongoing projects:

Hepatitis B
1. Natural history of hepatitis B and risk factors for disease progression
2. Evaluation of novel HBV markers
3. Safety and efficacy of new treatments for hepatitis B
4. Risk factors and prevention of reactivation of hepatitis B

Hepatitis C
1. Prediction models for disease progression

Hepatocellular Carcinoma (HCC)
1. Biomarkers for early diagnosis
2. Prediction models for HCC

Nonalcoholic Fatty Liver Disease (NAFLD)
1. Pathophysiology of lean vs. obese NAFLD